GSK receives CHMP positive opinion for a new indication for Arixtra

GlaxoSmithKline (GSK) today announced that the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Arixtra (fondaparinux),an anti-clotting drug (antithrombotic) for the treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis (SVT) of the lower limbs without concomitant deep-vein thrombosis.
  • The first treatment available for superficial vein thrombosis in Europe

Issued: London UK

GlaxoSmithKline (GSK) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Arixtra (fondaparinux),an anti-clotting drug (antithrombotic) for the treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis (SVT) of the lower limbs without concomitant deep-vein thrombosis.

“We are very glad that healthcare providers now have fondaparinux as a licensed treatment option for patients with superficial vein thrombosis. SVT is a condition that can lead to serious and even life threatening complications. We expect that fondaparinux will be an important option for the treatment of SVT” said Dr. Tony Hoos, SVP, European Medical Affairs, GSK.

The decision was granted via the centralised filing procedure with Sweden as the rapporteur and France the co-rapporteur. The decision was supported by the results of the CALISTO study (Comparison of Arixtra in lower LImb Superficial vein Thrombosis with placebO) , the first study in SVT to show a clinical effect with an anticoagulant treatment versus placebo.1

Fondaparinux is currently approved for use in the EU for the prevention of venous thromboembolic events (VTE), initial treatment of acute deep vein thrombosis (DVT), pulmonary embolism (PE) treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) and for the treatment of ST segment elevation myocardial infarction (STEMI).

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

   

UK Media enquiries:

Philip Thomson

(020) 8047 5502

 

Claire Brough

(020) 8047 5502

 

Stephen Rea

(020) 8047 5502

 

Alexandra Harrison

(020) 8047 5502

 

Jo Revill

(020) 8047 5502

 

 

 

US Media enquiries:

Nancy Pekarek

(919) 483 2839

 

Mary Anne Rhyne

(919) 483 2839

 

Kevin Colgan

(919) 483 2839

 

Sarah Alspach

(919) 483 2839

 

   

European Analyst/Investor enquiries:

David Mawdsley

(020) 8047 5564

 

Sally Ferguson

(020) 8047 5543

 

Gary Davies

(020) 8047 5503

     

US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419

 

Jen Hill Baxter

(215) 751 7002

References:

1. Décousus H, Prandoni P, Leizorovicz A, Fondaparinux 2.5 mg for the Treatment of Symptomatic, Isolated Superficial Vein Thrombosis (SVT): Preliminary Data from the Randomized Placebo-Controlled CALISTO Trial (on Behalf of the CALISTO Investigators) American Society of Hematology Annual Meeting 2009 Abstracts 114: Abstract 171.